STING
Stimulator of Interferon Genes; TMEM173; MITA; ERIS; MPYS
Stimulator of interferon genes (STING) is an integral ER-membrane protein that can be activated by 2'3'-cGAMP synthesized by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) upon binding of double-stranded DNA. It activates interferon (IFN) and inflammatory cytokine responses to defend against infection by microorganisms.
STING is a key cytosolic receptor for small nucleotides and plays a key role in anticancer and antiviral immunity. STING signaling pathway is also a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING agonists, such as endogenous cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP), have been used in diverse research for immunogenic tumor clearance, antiviral treatments and vaccine adjuvants.
All Product Categories
-
STING Inhibitors
(50)
View all products
-
STING Agonists
(104)
View all products
-
STING Antagonists
(7)
View all products
-
STING Activators
(51)
View all products
-
STING Modulators
(5)
View all products
-
STING Degraders
(12)
View all products
-
STING Controls
(3)
View all products
-
STING Ligands
(3)
View all products
-
STING Produits associés (251)
Produits associés (251)
-
Anticorps (13)
-
STING agonist-25
0 ImagesCat. No.: HY-152958CAS No.: 2408723-10-2STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
-
UM-200
0 ImagesCat. No.: HY-182923UM-200 is a covalent STING inhibitor with an EC50 of 1.10 μM. UM-200 covalently modifies the cysteine residues C292 or C309 of STING, thereby blocking its oligomerization and downstream signal transduction. UM-200 inhibits STING-dependent phosphorylation of TBK1 and IRF3. UM-200 inhibits the STING signaling pathway in mouse models. UM-200 can be used for research on STING-driven inflammatory and autoimmune diseases.
-
TLC388
0 ImagesCat. No.: HY-19943CAS No.: 1432468-79-5TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC.
-
STING Degrader-3
0 ImagesCat. No.: HY-168554STING Degrader-3 is a PROTAC-like STING degrader with a DC50 of 2.58 μM in THP-1 cells. STING Degrader-3 degrades STING protein via the lysosomal pathway. STING Degrader-3 functions as a non-degradative inhibitor in macrophages. STING Degrader-3 reduces the phosphorylation levels of TBK1 and IRF3, and downregulates the expression of IFN-β, CXCL10, IL-6, TNFα, IL-1β, ISG15 and ISG56. STING Degrader-3 exhibits renoprotective properties in a cisplatin-induced acute kidney injury model. STING Degrader-3 can be used in studies related to acute kidney injury. ((Pink: STING ligand (HY-168676); Blue: CRBN ligand (HY-126457); Black: linker (HY-W123015); CRBN ligand + linker: (HY-168677)).
-
MS8588
0 ImagesCat. No.: HY-162967CAS No.: 3060519-94-7MS8588 is a deubiquitinase-targeting chimera (DUBTAC) against cGAS. MS8588 induces targeted stabilization of cGAS, thereby activating downstream signaling pathways. MS8588 activates the cGAS/STING/IRF3 innate immune signaling pathway. MS8588 exhibits antitumor activity.
-
Polθ-IN-11
0 ImagesCat. No.: HY-183748CAS No.: 3082173-75-6Polθ-IN-11 is an orally active DNA polymerase θ (Polθ) ATPase inhibitor with an IC50 of 4.3 nM against human targets. Polθ-IN-11 activates the cGAS-STING pathway. Polθ-IN-11 upregulates the expression of PD-L1 in HR-deficient cancer cells. Polθ-IN-11 acts synergistically with PARP inhibition in HR-deficient cancer cells and in vivo xenograft models. Polθ-IN-11 can be used in studies related to HR-deficient cancers.
-
Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag
0 ImagesCat. No.: HY-158349CAS No.: 2553413-19-5Mal-Val-Ala-PAB-4-Abu(Me)-Dazostinag is a drug-linker conjugate for ADC.
-
PDIC-NN
0 ImagesCat. No.: HY-169225CAS No.: 932740-48-2Synonyms: PDIC-NS free basePDIC-NN (PDIC-NS free base) is a STING activator with anticancer activity. PDIC-NN promotes the content and biostability of endogenous cyclic dinucleotides (CDNs). PDIC-NN triggers ROS burst and causes serious damage to mitochondria. PDIC-NN induces cell apoptosis and inhibits DNA replication. PDIC-NN activates cGAS-STING signaling pathway, enhances the immunogenicity of tumor cells and activates a robust innate immune response.
-
STING agonist-30
0 ImagesCat. No.: HY-149267CAS No.: 2951078-67-2
-
MS7829
0 ImagesCat. No.: HY-162966CAS No.: 3060519-67-4MS7829 is a deubiquitinase-targeting chimera (DUBTAC) that targets cGAS. MS7829 recruits OTUB1 to cGAS, binds covalently to OTUB1, stabilizes the protein abundance of cGAS, and activates the cGAS-STING-IRF3 innate immune signaling pathway in an OTUB1-dependent manner. MS7829 is applicable to cancer-related research.
-
Ferroptosis inducer-17
0 ImagesCat. No.: HY-184662Ferroptosis inducer-17 is a ferroptosis inducer that downregulates GPX4 and activates the CTSB and cGAS-STING pathways. Ferroptosis inducer-17 exhibits cytotoxicity against cancer cells but low toxicity toward normal cells. Ferroptosis inducer-17 accumulates in mitochondria and lysosomes, thereby inducing ROS production, lipid peroxidation, mitochondrial membrane depolarization, lysosomal iron accumulation, increased membrane permeability, and enhanced oxidative stress. Ferroptosis inducer-17 inhibits tumor growth in cisplatin-resistant xenograft models. Ferroptosis inducer-17 can be used for cancer-related research.
-
CDN-A
0 ImagesCat. No.: HY-148420CAS No.: 2586047-09-6CDN-A is a cyclic di-nucleotide, it can be used to synthesis antibody-drug conjugate (ADC). Cyclic di-nucleotides are potent stimulators of innate and adaptive immune responses. In humans, cyclic di-nucleotide, which are either produced endogenously in response to foreign DNA or by invading bacterial pathogens, trigger the innate immune system by activating the expression of interferon genes.
-
STING-IN-8
0 ImagesCat. No.: HY-163749STING-IN-8 (Compound 15b) emerges as a potent stimulator of interferon gene (STING) inhibitor with an IC50 value of 0.121 μM in human and an IC50 value of 0.033 μM in mouse. STING-IN-8 inhibits MSA-2 (HY-136927) or 2’, 3’ -cGAMP (HY-100564)-stimulated STING signaling and suppresses immune-inflammatory cytokine levels in both human and murine cells. STING-IN-8 is promising for research in the field of STING-associated inflammatory and autoimmune diseases.
-
STING agonist-48
0 ImagesCat. No.: HY-178966CAS No.: 3027712-31-5STING agonist-48 is a potent STING agonist that exhibits STING-dependent activity in vitro (EC50 = 4.02 μM). STING agonist-48 prefers to bind with the transmembrane domain (TMD) over the cytosolic cyclic dinucleotide (CDN) domain. STING agonist-48 shows adjuvant efficacy, enhancing IgG and Th1/Th2 cytokine responses in humanized STING mice. STING agonist-48 can be used for the study of inflammation-related diseases.
-
Vadimezan (Standard)
0 ImagesSynonyms: DMXAA (Standard); ASA-404 (Standard)Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
-
Ulevostinag (isomer 2)
0 ImagesCat. No.: HY-139586BCAS No.: 2082743-99-3Synonyms: MK-1454 (isomer 2)Ulevostinag isomer 2 (MK-1454 isomer 2) is the isomer of Ulevostinag. Ulevostinag is a STING agonist.
-
STING agonist-3 (Standard)
0 ImagesSTING agonist-3 (Standard) is the analytical standard of STING agonist-3 (HY-103665). This product is intended for research and analytical applications. STING agonist-3, extracted from patent WO2017175147A1 (example 10), is a selective and non-nucleotide small-molecule STING agonist with a pEC50 and pIC50 of 7.5 and 9.5, respectively. STING agonist-3 has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
